MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
MindMaze Therapeutics (RLFTF) announced on March 19, 2026 that Baader Bank has initiated equity research coverage with a Buy recommendation and a CHF 1.80 target price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MindMaze Therapeutics (RLFTF) announced on March 19, 2026 that Baader Bank has initiated equity research coverage with a Buy recommendation and a CHF 1.80 target price.
According to the company, this new coverage complements existing research from Edison Group, which values the company at CHF 3.56 per share.
Positive
- Baader Bank initiated coverage with a Buy recommendation
- New analyst coverage may increase visibility and liquidity for RLFTF shares
Negative
- Target price divergence: Baader CHF 1.80 vs Edison CHF 3.56
Details
News Market Reaction – RLFTF
On Mar 19, the day this news came out, RLFTF closed 1.95% below the previous close.
Data tracked by StockTitan Argus for the Mar 19 session.
Key Figures
- Baader target price
- CHF 1.80 per share
- Initiation of coverage by Baader Bank
- Edison valuation
- CHF 3.56 per share
- Existing research coverage by Edison Group
- SwissNeuroRehab funding
- CHF 11.2 million
- Innosuisse-backed Swiss flagship reimbursement program
- New shares issued
- 140,000,000 shares
- Share exchange in NeuroX business combination
- Shares outstanding
- 152,602,044 shares
- Post-combination share count excluding treasury shares
- Completed clinical studies
- 27+ studies
- Evidence base for digital neurorehabilitation and reimbursement
- Regulatory clearances
- 11 clearances
- Global regulatory footprint for neurotherapeutic platform
- FDA review period
- 10-month review
- Planned timeline for 505(b)(2) NDA for RLF-OD032
Historical Context
-
Outlined global reimbursement push with SwissNeuroRehab and U.S. CMS coding.
-
Closed NeuroX combination, creating integrated neurotherapeutics platform with new shares.
-
Shareholders approved NeuroX combination and capital increase for new structure.
-
Reported positive pivotal bioequivalence results for RLF-OD032 vs KUVAN.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.
Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company's FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com
Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.